BARC

Eliana Merle

Q: How accurate are Eliana Merle's stock ratings?

About 47% of Eliana's ratings were profitable over a one-year hold, with an average return of +8.0% per rating, measured by 13Foresight from historical prices.

Q: How is Eliana ranked?

Eliana Merle is ranked #2096 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Barclays

Wall Street Analyst

★★★☆☆

#2096

on 13Foresight · ranked by our own returns

47%

Success Rate

+7.7%

Average Return

58 of 124 calls profitable · +4.5% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

🔒 5-year track record is Pro. Showing 1-year — upgrade.

📈 Across the calls we could measure, roughly 47% of Eliana Merle's ratings turned a profit when each position was held for 1 year — averaging +7.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

154 Buy 32 Hold 5 Sell

Eliana's Stock Coverage 39 ratings · 2026-10-18

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
ALNY Alnylam Pharma	Oct 13, 2026	BUY	Strong Buy +35.0% avg upside 52 analysts	$450.00 91.70% Upside	+3.6%	·
MBX MBX Biosciences, Inc.	Oct 13, 2026	BUY	Strong Buy +72.5% avg upside 14 analysts	$88.00 74.17% Upside	+1.2%	·
FDMT 4D Molecular Therapeutics	Oct 13, 2026	BUY	Strong Buy +176.7% avg upside 16 analysts	$28.00 127.46% Upside	·	·
RGNX RegenXBio	Oct 13, 2026	HOLD	Strong Buy +420.8% avg upside 24 analysts	$12.00 73.47% Upside	-4.6%	·
BMRN BioMarin Pharmaceutical	Oct 13, 2026	BUY	Strong Buy +74.7% avg upside 52 analysts	$114.00 108.86% Upside	+3.1%	·
NTLA Intellia Therapeutics	Oct 07, 2026	SELL	Buy +213.9% avg upside 39 analysts	$8.00 30.49% Downside	+2.4%	·
BBIO BridgeBio Pharma	Oct 07, 2026	BUY	Strong Buy +43.8% avg upside 36 analysts	$156.00 134.81% Upside	-0.2%	·
PTCT PTC Therapeutics	Oct 07, 2026	BUY	Buy +35.2% avg upside 29 analysts	$122.00 105.28% Upside	-0.5%	·
QURE uniQure	Oct 06, 2026	HOLD	Strong Buy +151.2% avg upside 30 analysts	$28.00 27.23% Upside	-9.1%	·
REGN Regeneron	Oct 02, 2026	BUY	Strong Buy +1.1% avg upside 60 analysts	$917.00 16.08% Upside	+8.3%	·
INSM Insmed	Sep 30, 2026	BUY	Strong Buy +75.8% avg upside 37 analysts	$207.00 114.16% Upside	-13.7%	·
TYRA Tyra Bioscience	Sep 30, 2026	BUY	Strong Buy +135.8% avg upside 17 analysts	$59.00 217.77% Upside	-15.3%	·
ASND Ascendis Pharma	Sep 30, 2026	BUY	Strong Buy +25.3% avg upside 28 analysts	$329.00 46.00% Upside	-1.1%	·
MDGL Madrigal Pharmaceuticals	Sep 30, 2026	BUY	Strong Buy +14.5% avg upside 34 analysts	$962.00 112.72% Upside	-10.8%	·
VRTX Vertex Pharmaceuticals	Sep 23, 2026	BUY	Strong Buy -11.1% avg upside 62 analysts	$617.00 23.81% Upside	-3.5%	·
RARE Ultragenyx Pharmaceutical	Sep 18, 2026	BUY	Strong Buy +231.0% avg upside 36 analysts	$35.00 139.89% Upside	+4.5%	·
IONS Ionis Pharmaceuticals	Sep 18, 2026	BUY	Buy +76.4% avg upside 44 analysts	$85.00 97.75% Upside	-3.0%	·
SGMT Sagimet Biosciences, Inc. Class A	Sep 09, 2026	BUY	Strong Buy +263.5% avg upside 17 analysts	$18.00 123.29% Upside	-30.5%	·
MRNA Moderna	Aug 24, 2026	HOLD	Hold -52.6% avg upside 38 analysts	$125.00 41.49% Downside	+57.0%	·
ALT Altimmune	Aug 13, 2026	BUY	Strong Buy +1090.0% avg upside 20 analysts	$20.00 802.85% Upside	-23.6%	·
SRPT Sarepta Therapeutics	Aug 07, 2026	HOLD	Buy +250.8% avg upside 50 analysts	$20.00 17.36% Upside	+1.9%	·
SABS SAB Biotherapeutics	Aug 07, 2026	BUY	Strong Buy +320.4% avg upside 14 analysts	$13.00 399.95% Upside	-36.1%	·
KYMR Kymera Therapeutics	Aug 06, 2026	BUY	Strong Buy +5.4% avg upside 37 analysts	$139.00 31.55% Upside	-1.5%	·
GOSS Gossamer Bio	Jul 28, 2026	SELL	Buy +1541.4% avg upside 17 analysts	$22.40 155.37% Upside	·	·
IVA Inventiva	Jun 04, 2026	BUY	Strong Buy +453.4% avg upside 17 analysts	$18.00 505.11% Upside	-30.5%	·
BNTX BioNTech SE	Nov 06, 2025	HOLD	Strong Buy +52.0% avg upside 28 analysts	$117.00 33.64% Upside	-15.1%	·
ANAB AnaptysBio	Aug 12, 2025	HOLD	Strong Buy +53.8% avg upside 26 analysts	$20.00 57.35% Downside	+325.0%	·
GILD Gilead Sciences	Aug 08, 2025	HOLD	Strong Buy -23.5% avg upside 66 analysts	$112.00 28.13% Downside	+14.5%	·
ARWR Arrowhead Pharmaceuticals	Jul 21, 2025	HOLD	Buy +32.5% avg upside 28 analysts	$12.00 78.63% Downside	+406.6%	·
PROK ProKidney	Jul 15, 2025	BUY	Strong Buy +383.9% avg upside 12 analysts	$8.00 501.55% Upside	-52.5%	·
ARVN Arvinas Holding Company	May 15, 2025	BUY	Buy +302.8% avg upside 28 analysts	$21.00 200.46% Upside	+45.1%	·
ZNTL Zentalis Pharmaceuticals	Jan 28, 2025	HOLD	Buy +525.0% avg upside 20 analysts	$2.20 3.26% Upside	+6.7%	·
RVMD Revolution Medicines	Jan 08, 2025	BUY	Strong Buy +15.4% avg upside 36 analysts	$71.00 59.83% Downside	+141.8%	·
KOD Kodiak Sciences	Apr 04, 2024	HOLD	Strong Buy -8.3% avg upside 12 analysts	$5.00 94.15% Downside	-42.4%	·
GLUE Monte Rosa Therapeutics	Oct 13, 2022	BUY	Strong Buy +128.8% avg upside 16 analysts	$22.00 124.46% Upside	-38.6%	·
RNAC Cartesian Therapeutics	Mar 03, 2021	BUY	Strong Buy +393.8% avg upside 19 analysts	$10.00 59.01% Upside	-57.2%	·
LKFT Lakefront Biotherapeutics	Aug 19, 2020	HOLD	Buy +242.7% avg upside 25 analysts	$134.00 349.22% Upside	-59.9%	·
PRQR ProQR	Dec 11, 2019	BUY	Strong Buy +724.7% avg upside 19 analysts	$40.00 2873.95% Upside	-51.1%	·
WHWK Whitehawk Therapeutics	Mar 18, 2019	BUY	Strong Buy +319.3% avg upside 15 analysts	$8.00 174.89% Upside	-63.1%	·

🔒 34 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Eliana Merle — Frequently Asked Questions

How accurate are Eliana Merle's stock ratings?

Based on the calls 13Foresight could measure, about 47% of Eliana's ratings were profitable over a one-year hold, with an average return of +8.0% per rating, or +27.1% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Eliana ranked on 13Foresight?

Eliana Merle is currently ranked #2096 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Eliana cover?

Eliana most recently has ratings on ALNY, MBX, FDMT, RGNX, BMRN, NTLA, BBIO, PTCT, QURE, REGN, INSM, TYRA and 27 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Eliana Merle

Rating Distribution

Welcome to 13Foresight!